- Home
- AIRS vs RPID Comparison
AIRS vs RPID Comparison
Compare AIRS & RPID Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AIRS
- RPID
- Stock Information
- Founded
- AIRS 2012
- RPID 2006
- Country
- AIRS United States
- RPID United States
- Employees
- AIRS N/A
- RPID N/A
- Industry
- AIRS Medical/Nursing Services
- RPID Medical Specialities
- Sector
- AIRS Health Care
- RPID Health Care
- Exchange
- AIRS Nasdaq
- RPID Nasdaq
- Market Cap
- AIRS 166.3M
- RPID 138.9M
- IPO Year
- AIRS 2021
- RPID 2021
- Fundamental
- Price
- AIRS $5.56
- RPID $3.44
- Analyst Decision
- AIRS Hold
- RPID Buy
- Analyst Count
- AIRS 3
- RPID 1
- Target Price
- AIRS $3.75
- RPID $8.00
- AVG Volume (30 Days)
- AIRS 526.7K
- RPID 67.1K
- Earning Date
- AIRS 08-08-2025
- RPID 08-01-2025
- Dividend Yield
- AIRS N/A
- RPID N/A
- EPS Growth
- AIRS N/A
- RPID N/A
- EPS
- AIRS N/A
- RPID N/A
- Revenue
- AIRS $172,101,000.00
- RPID $29,645,000.00
- Revenue This Year
- AIRS N/A
- RPID $18.54
- Revenue Next Year
- AIRS $4.90
- RPID $20.55
- P/E Ratio
- AIRS N/A
- RPID N/A
- Revenue Growth
- AIRS N/A
- RPID 28.36
- 52 Week Low
- AIRS $1.53
- RPID $0.64
- 52 Week High
- AIRS $9.20
- RPID $4.04
- Technical
- Relative Strength Index (RSI)
- AIRS 59.82
- RPID 52.45
- Support Level
- AIRS $4.75
- RPID $3.13
- Resistance Level
- AIRS $5.65
- RPID $3.50
- Average True Range (ATR)
- AIRS 0.42
- RPID 0.19
- MACD
- AIRS 0.01
- RPID -0.02
- Stochastic Oscillator
- AIRS 58.90
- RPID 48.44
About AIRS AirSculpt Technologies Inc.
AirSculpt Technologies Inc is a national provider of body contouring procedures delivering a premium consumer experience under its brand Elite Body Sculpture. Elite Body Sculpture, provides custom body contouring using the proprietary AirSculpt method that removes unwanted fat in a minimally invasive procedure. The company has one operating and reportable segment, direct medical procedure services.
About RPID Rapid Micro Biosystems Inc.
Rapid Micro Biosystems Inc is an life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products such as biologics, vaccines, cell and gene therapies, and sterile injectables. The company's flagship Growth Direct platform automates and modernizes the antiquated, manual microbial quality control (MQC) testing workflows used in the pharmaceutical manufacturing operations across the globe. It derives revenue from development, manufacturing, marketing and selling Systems and related LIMS connection software, consumables and services.